mFOLFOXIRI plus Bevacizumab

DRUG2 trials

Sponsors

Yanhong Deng, Fudan University

Conditions

Colorectal CancerLiver Metastases

Phase 3

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Active, not recruitingNCT04230187

Yanhong DengColorectal Cancer

Start: 2020-09-01End: 2029-06-01Target: 528Updated: 2026-05-22

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

RecruitingNCT04687631

Fudan UniversityColorectal Cancer, Liver Metastases

Start: 2021-01-14End: 2027-09-30Target: 508Updated: 2024-12-18